Brief: Burning Rock Reports First Quarter 2023 Financial Results
May 30 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
* REITERATE 2023 FULL-YEAR REVENUE GUIDANCE OF
APPROXIMATELY 20%
GROWTH OVER 2022
* QTRLY REVENUES WERE RMB142.5 MILLION (US$20.8 MILLION),
REPRESENTING A 5.2% INCREASE FROM RMB135.5 MILLION FOR SAME
PERIOD IN 2022
* QTRLY LOSS PER SHARE FOR CLASS A ORDINARY SHARES RMB 1.81
Source text for Eikon: ID:nGNX48pjjK
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer